iECURE Appoints Brian Di Donato to Board of Directors

Rhea-AI Summary

iECURE announced the appointment of Brian Di Donato to its Board of Directors. Di Donato, who has over 20 years of financial leadership experience, currently serves as CFO and Head of Strategy at Immunocore (NASDAQ-NMS:IMCR). His expertise is expected to enhance iECURE's mission to develop gene insertion therapies for severe metabolic disorders. Di Donato holds an MBA from NYU and degrees in biology and mechanical engineering. CEO Joseph Truitt expressed optimism about Di Donato's contributions to advancing their pipeline.

Positive

• Appointment of Brian Di Donato expected to strengthen financial strategy and board oversight.
• Di Donato's extensive experience in biotech and capital markets aligns with iECURE's future growth.

Negative

• No immediate financial metrics or forecasts provided to evaluate the impact of the new board member.

PHILADELPHIA--(BUSINESS WIRE)-- iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced it has appointed Brian Di Donato, MBA to its Board of Directors. Mr. Di Donato has more than 20 years of financial and leadership experience and currently serves as chief financial officer and head of strategy at Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies.

Brian Di Donato, MBA (Photo: Business Wire)

“Brian brings significant financial and capital market expertise to our Board, which will be helpful as we build iECURE and continue development of our pipeline of gene insertion therapies,” said Joseph Truitt, chief executive officer of iECURE. “We look forward to his guidance and support.”

Prior to joining Immunocore, Mr. Di Donato served as senior vice president and chief financial officer at Achillion Pharmaceuticals and held leadership roles in several financial services companies, including Morgan Stanley and UBS Securities.

“iECURE has an exceptional opportunity to realize Jim Wilson’s vision of curing some of the most devastating metabolic disorders by inserting copies of healthy genes into patients’ genomes,” said Mr. Di Donato, “I'm looking forward to help steer the company as it embarks on this lofty mission.”

Mr. Di Donato holds an MBA from New York University’s Stern School of Business and B.S. degrees in biology from Penn State University and mechanical engineering from Villanova University. Mr. Di Donato also served in the U.S. Navy as an aerospace engineering officer.

About iECURE

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania’s Gene Therapy Program. Using in vivo editing, our methods focus on inserting functioning genes into patients’ genomes, which offers long-term, stable expression of those genes. With our team’s proven track record, as well as the University of Pennsylvania’s deep expertise and translational genetic medicine engine, reversing the course of these devastating diseases is now within reach. For more information, visit www.iECURE.com and follow on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005288/en/

Danielle Cantey

Canale Communications

danielle.cantey@canalecomm.com

Source: iECURE

FAQ

What is the significance of Brian Di Donato's appointment to iECURE's Board of Directors?

Brian Di Donato's appointment is significant as he brings extensive financial leadership experience, which can enhance iECURE's strategies in gene therapy development.

How does Brian Di Donato's background benefit Immunocore (IMCR)?

Di Donato's experience as CFO at Immunocore equips him with insights into navigating the complexities of the biotechnology sector, which can help guide iECURE's financial decisions.

What are iECURE's primary goals following the appointment of Brian Di Donato?

iECURE aims to advance its pipeline of gene insertion therapies, focusing on curing metabolic disorders with high unmet medical needs.

When was Brian Di Donato appointed to the Board of Directors of iECURE?

Brian Di Donato was appointed to the Board of Directors of iECURE as announced in their press release dated September 15, 2021.